Processa Pharmaceuticals, Inc. - 10-Q Filing
Processa Pharmaceuticals filed its Q1 2026 10-Q report, disclosing a net loss of $3.38 million for the three months ended March 31, 2026, compared to a net loss of $2.83 million in the same period last year. The company reported cash and equivalents of $1.69 million as of March 31, 2026, down from $5.54 million at December 31, 2025.
Tickers: $PCSA